Consulting Services
Compare Stocks
4 / 10Stock Comparison
SBC vs SSKN vs SKIN vs INMD
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Household & Personal Products
Medical - Devices
SBC vs SSKN vs SKIN vs INMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Consulting Services | Medical - Devices | Household & Personal Products | Medical - Devices |
| Market Cap | $329M | $7M | $118M | $882M |
| Revenue (TTM) | $178M | $31M | $296M | $375M |
| Net Income (TTM) | $43M | $-11M | $-6M | $87M |
| Gross Margin | 73.7% | 57.8% | 64.9% | 77.8% |
| Operating Margin | 33.3% | -33.3% | -3.6% | 21.3% |
| Forward P/E | 7.1x | — | — | 9.6x |
| Total Debt | $12M | $16M | $379M | $13M |
| Cash & Equiv. | $125M | $7M | $233M | $303M |
SBC vs SSKN vs SKIN vs INMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| SBC Medical Group H… (SBC) | 100 | 32.0 | -68.0% |
| STRATA Skin Science… (SSKN) | 100 | 2.0 | -98.0% |
| The Beauty Health C… (SKIN) | 100 | 7.7 | -92.3% |
| InMode Ltd. (INMD) | 100 | 47.8 | -52.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SBC vs SSKN vs SKIN vs INMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SBC carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.76
- Lower volatility, beta 0.76, Low D/E 6.3%, current ratio 3.01x
- Beta 0.76, current ratio 3.01x
- 6.1% revenue growth vs SKIN's -10.0%
SSKN is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 0.6%, EPS growth 16.1%, 3Y rev CAGR 3.8%
SKIN plays a supporting role in this comparison — it may shine differently against other peers.
INMD is the clearest fit if your priority is long-term compounding.
- 105.0% 10Y total return vs SBC's -67.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 6.1% revenue growth vs SKIN's -10.0% | |
| Value | Lower P/E (7.1x vs 9.6x) | |
| Quality / Margins | 24.3% margin vs SSKN's -35.6% | |
| Stability / Safety | Beta 0.76 vs SKIN's 2.00, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +0.3% vs SSKN's -93.3% | |
| Efficiency (ROA) | 13.5% ROA vs SSKN's -35.9%, ROIC 72.3% vs -38.9% |
SBC vs SSKN vs SKIN vs INMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
SBC vs SSKN vs SKIN vs INMD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
SBC leads in 1 of 6 categories
INMD leads 1 • SSKN leads 0 • SKIN leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — SBC and INMD each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INMD is the larger business by revenue, generating $375M annually — 12.1x SSKN's $31M. SBC is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to SSKN's -35.6%. On growth, INMD holds the edge at +5.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $178M | $31M | $296M | $375M |
| EBITDAEarnings before interest/tax | $62M | -$5M | $9M | $81M |
| Net IncomeAfter-tax profit | $43M | -$11M | -$6M | $87M |
| Free Cash FlowCash after capex | -$37M | -$4M | $29M | $91M |
| Gross MarginGross profit ÷ Revenue | +73.7% | +57.8% | +64.9% | +77.8% |
| Operating MarginEBIT ÷ Revenue | +33.3% | -33.3% | -3.6% | +21.3% |
| Net MarginNet income ÷ Revenue | +24.3% | -35.6% | -2.0% | +23.3% |
| FCF MarginFCF ÷ Revenue | -20.5% | -11.3% | +9.8% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -18.3% | -21.2% | -6.7% | +5.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.2% | -5.9% | +38.0% | -30.8% |
Valuation Metrics
Evenly matched — SBC and SKIN each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 6.7x trailing earnings, SBC trades at a 32% valuation discount to INMD's 9.7x P/E. On an enterprise value basis, SBC's 2.9x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $329M | $7M | $118M | $882M |
| Enterprise ValueMkt cap + debt − cash | $216M | $16M | $264M | $593M |
| Trailing P/EPrice ÷ TTM EPS | 6.65x | -0.67x | -5.69x | 9.73x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.07x | — | — | 9.64x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.98x |
| EV / EBITDAEnterprise value multiple | 2.92x | — | 7331.15x | 6.88x |
| Price / SalesMarket cap ÷ Revenue | 1.60x | 0.20x | 0.39x | 2.38x |
| Price / BookPrice ÷ Book value/share | 1.59x | 1.34x | 2.02x | 1.33x |
| Price / FCFMarket cap ÷ FCF | 19.17x | — | 3.17x | 10.46x |
Profitability & Efficiency
SBC leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
SBC delivers a 17.5% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-8 for SSKN. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SBC scores 7/9 vs INMD's 3/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +17.5% | -8.4% | -9.4% | +13.3% |
| ROA (TTM)Return on assets | +13.5% | -35.9% | -1.2% | +11.8% |
| ROICReturn on invested capital | +72.3% | -38.9% | -6.8% | +13.5% |
| ROCEReturn on capital employed | +37.9% | -36.0% | -4.5% | +12.1% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 | 7 | 3 |
| Debt / EquityFinancial leverage | 0.06x | 3.31x | 6.20x | 0.02x |
| Net DebtTotal debt minus cash | -$113M | $9M | $146M | -$289M |
| Cash & Equiv.Liquid assets | $125M | $7M | $233M | $303M |
| Total DebtShort + long-term debt | $12M | $16M | $379M | $13M |
| Interest CoverageEBIT ÷ Interest expense | 596.05x | -4.63x | 0.81x | — |
Total Returns (Dividends Reinvested)
INMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INMD five years ago would be worth $3,613 today (with dividends reinvested), compared to $109 for SSKN. Over the past 12 months, SBC leads with a +0.3% total return vs SSKN's -93.3%. The 3-year compound annual growth rate (CAGR) favors INMD at -26.4% vs SSKN's -74.5% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -25.9% | -86.2% | -35.0% | -5.9% |
| 1-Year ReturnPast 12 months | +0.3% | -93.3% | -35.9% | -2.1% |
| 3-Year ReturnCumulative with dividends | -68.9% | -98.3% | -91.7% | -60.2% |
| 5-Year ReturnCumulative with dividends | -67.8% | -98.9% | -92.9% | -63.9% |
| 10-Year ReturnCumulative with dividends | -67.8% | -99.6% | -91.6% | +105.0% |
| CAGR (3Y)Annualised 3-year return | -32.2% | -74.5% | -56.4% | -26.4% |
Risk & Volatility
Evenly matched — SSKN and INMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
SSKN is the less volatile stock with a -0.24 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. INMD currently trades 83.2% from its 52-week high vs SSKN's 4.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.76x | -0.24x | 2.00x | 1.04x |
| 52-Week HighHighest price in past year | $5.75 | $3.86 | $2.69 | $16.74 |
| 52-Week LowLowest price in past year | $2.97 | $0.11 | $0.76 | $12.72 |
| % of 52W HighCurrent price vs 52-week peak | +55.8% | +4.5% | +33.8% | +83.2% |
| RSI (14)Momentum oscillator 0–100 | 29.9 | 41.6 | 52.1 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 87K | 14K | 760K | 804K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: SBC as "Buy", SKIN as "Hold", INMD as "Buy". Consensus price targets imply 180.4% upside for SBC (target: $9) vs 14.9% for INMD (target: $16).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Hold | Buy |
| Price TargetConsensus 12-month target | $9.00 | — | $1.30 | $16.00 |
| # AnalystsCovering analysts | 1 | — | 13 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +14.5% |
SBC leads in 1 of 6 categories (Profitability & Efficiency). INMD leads in 1 (Total Returns). 3 tied.
SBC vs SSKN vs SKIN vs INMD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SBC or SSKN or SKIN or INMD a better buy right now?
For growth investors, SBC Medical Group Holdings Incorporated (SBC) is the stronger pick with 6.
1% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). SBC Medical Group Holdings Incorporated (SBC) offers the better valuation at 6. 7x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate SBC Medical Group Holdings Incorporated (SBC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SBC or SSKN or SKIN or INMD?
On trailing P/E, SBC Medical Group Holdings Incorporated (SBC) is the cheapest at 6.
7x versus InMode Ltd. at 9. 7x. On forward P/E, SBC Medical Group Holdings Incorporated is actually cheaper at 7. 1x.
03Which is the better long-term investment — SBC or SSKN or SKIN or INMD?
Over the past 5 years, InMode Ltd.
(INMD) delivered a total return of -63. 9%, compared to -98. 9% for STRATA Skin Sciences, Inc. (SSKN). Over 10 years, the gap is even starker: INMD returned +105. 0% versus SSKN's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SBC or SSKN or SKIN or INMD?
By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.
(SSKN) is the lower-risk stock at -0. 24β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately -918% more volatile than SSKN relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — SBC or SSKN or SKIN or INMD?
By revenue growth (latest reported year), SBC Medical Group Holdings Incorporated (SBC) is pulling ahead at 6.
1% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, SSKN leads at 3. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SBC or SSKN or SKIN or INMD?
InMode Ltd.
(INMD) is the more profitable company, earning 25. 3% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBC leads at 34. 2% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SBC or SSKN or SKIN or INMD more undervalued right now?
On forward earnings alone, SBC Medical Group Holdings Incorporated (SBC) trades at 7.
1x forward P/E versus 9. 6x for InMode Ltd. — 2. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SBC: 180. 4% to $9. 00.
08Which pays a better dividend — SBC or SSKN or SKIN or INMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is SBC or SSKN or SKIN or INMD better for a retirement portfolio?
For long-horizon retirement investors, STRATA Skin Sciences, Inc.
(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 24)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SBC and SSKN and SKIN and INMD?
These companies operate in different sectors (SBC (Industrials) and SSKN (Healthcare) and SKIN (Consumer Defensive) and INMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SBC is a small-cap deep-value stock; SSKN is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; INMD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.